Cargando…

The Phase 2 Study of "(TOX) Preoperative Chemotherapy" Response Rate and Side Effects in [Locally Advanced Operable Gastric Adenocarcinoma] Patients With Docetaxel, Oxaliplatin and Capcitabine

BACKGROUND: Early stage gastric cancer diagnosis has ensued different approaches in resection strategies. In order to increase the proportion of cases which have undergone radical resection or have reduced the recurrence rate, different pre-operative treatments have introduced. Here, we have verifie...

Descripción completa

Detalles Bibliográficos
Autores principales: Yahyazadeh-Jabbari, Seyyed-Hossein, Malekpour, Nasser, Salmanian, Bahram, Foodazi, Hossein, Salehi, Masoud, Noorizadeh, Farsad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Research Center, Shahid Beheshti University of Medical Sciences 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4142926/
https://www.ncbi.nlm.nih.gov/pubmed/25250123
_version_ 1782331836147433472
author Yahyazadeh-Jabbari, Seyyed-Hossein
Malekpour, Nasser
Salmanian, Bahram
Foodazi, Hossein
Salehi, Masoud
Noorizadeh, Farsad
author_facet Yahyazadeh-Jabbari, Seyyed-Hossein
Malekpour, Nasser
Salmanian, Bahram
Foodazi, Hossein
Salehi, Masoud
Noorizadeh, Farsad
author_sort Yahyazadeh-Jabbari, Seyyed-Hossein
collection PubMed
description BACKGROUND: Early stage gastric cancer diagnosis has ensued different approaches in resection strategies. In order to increase the proportion of cases which have undergone radical resection or have reduced the recurrence rate, different pre-operative treatments have introduced. Here, we have verified an active preoperative chemotherapeutic regimen in locally advanced gastric cancer patients. METHODS: Forty nine patients who have found eligible to enter this phase 2 trial have treated with oxaliplatin 100 mg/m2 IV, docetaxel 50 mg/m2 IV, plus capecitabine 625 mg/m2 PO (TOX). Clinical staging has been following the first 2 cycles of induction chemotherapy. Patients that have further undergone radical surgery, have evaluated for pathological response rate. RESULTS: Anemia (10.2%), nausea (10.2%) and vomiting (6.1%) were the most frequent grade 3 or 4 adverse effects. Regarding the pathologic staging, 6 patients (12.2%) had complete response (95% CI 3% to 21.4%), 18 of them (36.7%) had partial response (95% CI 23.2% to 50.2%), then 3 patients (6.1%) had stable disease (95% CI 0%-12.8%). Among the patients who had surgery, 22% had pathologic complete response. CONCLUSION: Preoperative chemotherapeutic regimen of TOX seems to be an active and safe neoadjuvant therapy in non metastatic gastric cancer. It should further be considered with concurrent radiotherapy.
format Online
Article
Text
id pubmed-4142926
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Cancer Research Center, Shahid Beheshti University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-41429262014-09-23 The Phase 2 Study of "(TOX) Preoperative Chemotherapy" Response Rate and Side Effects in [Locally Advanced Operable Gastric Adenocarcinoma] Patients With Docetaxel, Oxaliplatin and Capcitabine Yahyazadeh-Jabbari, Seyyed-Hossein Malekpour, Nasser Salmanian, Bahram Foodazi, Hossein Salehi, Masoud Noorizadeh, Farsad Iran J Cancer Prev Clinical Trial BACKGROUND: Early stage gastric cancer diagnosis has ensued different approaches in resection strategies. In order to increase the proportion of cases which have undergone radical resection or have reduced the recurrence rate, different pre-operative treatments have introduced. Here, we have verified an active preoperative chemotherapeutic regimen in locally advanced gastric cancer patients. METHODS: Forty nine patients who have found eligible to enter this phase 2 trial have treated with oxaliplatin 100 mg/m2 IV, docetaxel 50 mg/m2 IV, plus capecitabine 625 mg/m2 PO (TOX). Clinical staging has been following the first 2 cycles of induction chemotherapy. Patients that have further undergone radical surgery, have evaluated for pathological response rate. RESULTS: Anemia (10.2%), nausea (10.2%) and vomiting (6.1%) were the most frequent grade 3 or 4 adverse effects. Regarding the pathologic staging, 6 patients (12.2%) had complete response (95% CI 3% to 21.4%), 18 of them (36.7%) had partial response (95% CI 23.2% to 50.2%), then 3 patients (6.1%) had stable disease (95% CI 0%-12.8%). Among the patients who had surgery, 22% had pathologic complete response. CONCLUSION: Preoperative chemotherapeutic regimen of TOX seems to be an active and safe neoadjuvant therapy in non metastatic gastric cancer. It should further be considered with concurrent radiotherapy. Cancer Research Center, Shahid Beheshti University of Medical Sciences 2013 /pmc/articles/PMC4142926/ /pubmed/25250123 Text en © 2014 Cancer Research Center, Shahid Beheshti University of Medical Sciences http://creativecommons.org/licenses/by-nc/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
spellingShingle Clinical Trial
Yahyazadeh-Jabbari, Seyyed-Hossein
Malekpour, Nasser
Salmanian, Bahram
Foodazi, Hossein
Salehi, Masoud
Noorizadeh, Farsad
The Phase 2 Study of "(TOX) Preoperative Chemotherapy" Response Rate and Side Effects in [Locally Advanced Operable Gastric Adenocarcinoma] Patients With Docetaxel, Oxaliplatin and Capcitabine
title The Phase 2 Study of "(TOX) Preoperative Chemotherapy" Response Rate and Side Effects in [Locally Advanced Operable Gastric Adenocarcinoma] Patients With Docetaxel, Oxaliplatin and Capcitabine
title_full The Phase 2 Study of "(TOX) Preoperative Chemotherapy" Response Rate and Side Effects in [Locally Advanced Operable Gastric Adenocarcinoma] Patients With Docetaxel, Oxaliplatin and Capcitabine
title_fullStr The Phase 2 Study of "(TOX) Preoperative Chemotherapy" Response Rate and Side Effects in [Locally Advanced Operable Gastric Adenocarcinoma] Patients With Docetaxel, Oxaliplatin and Capcitabine
title_full_unstemmed The Phase 2 Study of "(TOX) Preoperative Chemotherapy" Response Rate and Side Effects in [Locally Advanced Operable Gastric Adenocarcinoma] Patients With Docetaxel, Oxaliplatin and Capcitabine
title_short The Phase 2 Study of "(TOX) Preoperative Chemotherapy" Response Rate and Side Effects in [Locally Advanced Operable Gastric Adenocarcinoma] Patients With Docetaxel, Oxaliplatin and Capcitabine
title_sort phase 2 study of "(tox) preoperative chemotherapy" response rate and side effects in [locally advanced operable gastric adenocarcinoma] patients with docetaxel, oxaliplatin and capcitabine
topic Clinical Trial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4142926/
https://www.ncbi.nlm.nih.gov/pubmed/25250123
work_keys_str_mv AT yahyazadehjabbariseyyedhossein thephase2studyoftoxpreoperativechemotherapyresponserateandsideeffectsinlocallyadvancedoperablegastricadenocarcinomapatientswithdocetaxeloxaliplatinandcapcitabine
AT malekpournasser thephase2studyoftoxpreoperativechemotherapyresponserateandsideeffectsinlocallyadvancedoperablegastricadenocarcinomapatientswithdocetaxeloxaliplatinandcapcitabine
AT salmanianbahram thephase2studyoftoxpreoperativechemotherapyresponserateandsideeffectsinlocallyadvancedoperablegastricadenocarcinomapatientswithdocetaxeloxaliplatinandcapcitabine
AT foodazihossein thephase2studyoftoxpreoperativechemotherapyresponserateandsideeffectsinlocallyadvancedoperablegastricadenocarcinomapatientswithdocetaxeloxaliplatinandcapcitabine
AT salehimasoud thephase2studyoftoxpreoperativechemotherapyresponserateandsideeffectsinlocallyadvancedoperablegastricadenocarcinomapatientswithdocetaxeloxaliplatinandcapcitabine
AT noorizadehfarsad thephase2studyoftoxpreoperativechemotherapyresponserateandsideeffectsinlocallyadvancedoperablegastricadenocarcinomapatientswithdocetaxeloxaliplatinandcapcitabine
AT yahyazadehjabbariseyyedhossein phase2studyoftoxpreoperativechemotherapyresponserateandsideeffectsinlocallyadvancedoperablegastricadenocarcinomapatientswithdocetaxeloxaliplatinandcapcitabine
AT malekpournasser phase2studyoftoxpreoperativechemotherapyresponserateandsideeffectsinlocallyadvancedoperablegastricadenocarcinomapatientswithdocetaxeloxaliplatinandcapcitabine
AT salmanianbahram phase2studyoftoxpreoperativechemotherapyresponserateandsideeffectsinlocallyadvancedoperablegastricadenocarcinomapatientswithdocetaxeloxaliplatinandcapcitabine
AT foodazihossein phase2studyoftoxpreoperativechemotherapyresponserateandsideeffectsinlocallyadvancedoperablegastricadenocarcinomapatientswithdocetaxeloxaliplatinandcapcitabine
AT salehimasoud phase2studyoftoxpreoperativechemotherapyresponserateandsideeffectsinlocallyadvancedoperablegastricadenocarcinomapatientswithdocetaxeloxaliplatinandcapcitabine
AT noorizadehfarsad phase2studyoftoxpreoperativechemotherapyresponserateandsideeffectsinlocallyadvancedoperablegastricadenocarcinomapatientswithdocetaxeloxaliplatinandcapcitabine